ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of budesonide aerosol inhalation for pediatric acute asthma attack. METHODS:Ninety patients diagnosed as acute asthma attack selected from our hospital during Jan. 2014-May 2016 were di-vided into observation group and control group in accordance with random number table,with 45 cases in each group. Control group was given Potassium sodium dehydroandroandrographolide and sodium chloride injection 10 mg/(kg·d),ivgtt,qd+Azithromy-cin injection 10 mg/(kg·d),ivgtt,qd for anti-infective therapy. Observation group was additionally given Budesonide aerosol 0.5 mg,aerosol inhalation,bid. Both groups received treatment for consecutive 7 d. Clinical efficacy,lung function index,T cell sub-group,symptom relief time were observed,and the occurrence of ADR was recorded. RESULTS:Total response rate of observa-tion group (91.11%) was significantly higher than that of control group (71.11%),with statistical significance (P0.05). CONCLUSIONS:Budesonide aerosol inhalation shows significant therapeutic effi-cacy for pediatric acute asthma attack with good safety.
ABSTRACT
AIM: To evaluate the safety and tolerance of ibandronate in Chinese healthy volunteers. METHODS: The trial protocol was designed according to the Good Clinical Practice(GCP). After physical examination and laboratory tests were performed, 36 healthy volunteers were divided randomly into 6 dose groups, including 1 mg , 2 mg , 3 mg , 4 mg , 5 mg and 6 mg , with 6 subjects in each group(3 male and 3 female). Clinical symptoms, vital signs, routine blood tests, routine urine tests, hepatic function, renal function, blood electrolytes, electrocardiogram, and electroencephalogram were observed or examined before and after a single intravenous infusion of ibandronate. RESULTS: After single intravenous infusion doses of 1- 6 mg , the vital signs, clinical symptoms and laboratory tests were all in the normal range, but there were some slight ADRs concerned with the drug, such as hypophosphataemia, increased body temperature, perspiring,pain of bone or muscle and hypocalcaemia. But the ADRs were found vanishing in one or two weeks. CONCLUSION: Single intravenous infusion (up to 6 mg ) of domestic ibandronate in 36 chinese healthy volunteers is safe and tolerable.
ABSTRACT
Synergetic antiplatelet effects of aqueous extracts of Fructus Crataegi and Rhizoma Alismatis in vitro were studied. The interaction of the two drugs was also observed. Results showed that the IC50 of Fructus Crataegi on platelet aggregation induced by ADP was 1.388g/100ml,whereas the IC50 of Rnizoma Alismatis was 7. 585g/100ml. In the presence of low concentrations of Fructus Crataegui (0.3~0.9g/100ml ),the an tiplatelet activity of Rhizoma Alismatis was significantly increased,and the IC50 was only 1.755g/100ml with the presence of 0. 9g of Cralaegus pinnatifida per 100ml. These results suggested that the two drugs have a mutual synergetic effect on antiplatelet function